RAPIDX.jpg
logo.png
unnamed.png
logo.jpg
inside-page-strip-2.jpg
logo.jpg

Unique enteral feeding to reduce reflux & Ventilator Associated Pneumonia (VAP) 

Overview   l   Problem   l    Market    l    Team

OVERVIEW

logo.jpg

 

LunGuard developed a novel solution for the future of critical care medicine (ICU). The new approach of the “Personalized Physiological Medicine (PPM)” based on a peristaltic enteral feeding tube that is structured from several inflatable balloons used as a multi-sensory platform. LunGuard’s innovative solution, together with the substantial clinical need, is designed to safely block Gastro Esophageal Reflux (GER) & reduce the cause Ventilator Associated Pneumonia (VAP). VAP leads to clinical complications requiring complex medical treatment, deteriorated patient conditions & prolonging the patient’s length of stay (LOS). LunGuard recently successfully accomplished a clinical trial with 20 patients & with significant clinical outcomes. A medical paper has been published. An additional study with 30 patients is expected for CE approval. 

Saves money and resources

  • Lower Length Of Stay

  • Saves money invested in treating nosocomial complications

  • Less staff resources 

 

LunGuard Clinical Studies shows

  • 80% of control group gets Micro Aspiration  of Gastric Fluids

  • USING LunGuard only 20% incidents of Micro Aspiration of Gastric Fluids

 

Keep gastric fluids in the stomach

  • Reduces the incidence of reflux regurgitation

  • Actively pumping oral/nasal and gastric secretions into the stomach

  • Reduces reflux clinical consequences

  • Significantly Reduces VAP

 

PROBLEM

The problem - Nosocomial Infections in ICU

  • Pneumonia constitutes highest percentage of nosocomial infections in ICUs

       Resulting in cost increase and financial loss for the hospitals

    - Length Of Stay (LOS) and treatment of medical complications

  • Ventilated Associated Pneumonia (VAP) is a major complication

    - approx. 25% of all invasive ventilated patients in China get VAP

    - approx. 30% in the USA and 40% in Germany suffer from VAP

  • Current applicable prevention measures for VAP are considered to be insufficient

Critical Care – unmet need

Current standard of care

  • Patients are usually Ventilated, Sedated, on antacids and fed through a NasoGastric tube

 

Possible clinical consequences

  • Peristaltic action of the oesophagus is impaired, open GE sphincter, sub-optimal ventilation, Increased bacterial risk of infection, Sub-optimal feeding

 

Patient’s infections

  • Gastric fluids with bacteria travel into the patient’s  airway and reach the lungs causing infections

  • 90% of enteral fed patients aspirate gastric contents

  • Aspiration of gastric contents is a major risk factor of pneumonia, resulting in complications and mortality 

 

Unmet need

  • Reduce the clinical consequences of the peristaltic action of the esophagus (reflux)  to diminish patient infection and AVP (Associated Ventilation Pneumonia) 

  • Cost savings of $1,200 - $17,000, per ventilated patient, for full prevention of VAP

SOLUTION

Enteral feeding Gastric Fluids Prevention Technology 

LunGuard – The Product

  • Position to become  the “standard-of-care” in enteral-fed ventilated patients

  • It enhance and optimise the efficiency  and safety for both ventilation and feeding

  • Reduces aspiration of gastric fluids compared to regular NG tube

  • Strong IP portfolio 

LunGuard’s Nutrition Advantage

  • KEEP GASTRIC FLUIDS IN THE STOMACH

  • PROTECT THE TRACHEA AND LUNGS FROM CONTAMINATION

  • PFT mimics the Peristaltic esophagus movement

  • Reducing reflux clinical consequences

  • Acts as a one-way valve allowing saliva secretion

  • Improve trade-off between under-feeding patients and lowering aspiration risk

  • Better nourished patients have better treatment outcomes at a lower cost 

  • allowing feeding throughout the 24h without a night-time break due to aspiration risk

  • Increases  nutrition up to 25% by allowing earlier and more efficient feeding rate in a moderated reflux environment 

 

MARKET

Global Enteral Feeding Market

Accounts for:

  • $1.8b in 2015

  • $ 2.3b by 2021 (forecasted)

 

Market Share

  • China - $80m

  • Germany - $170m

  • USA - $800m

 

Compound Annual Growth Rate (CAGR) 

  • China - 30%

  • USA - 3%

  • Germany - 1.7%

Potential Market and Value - Reduced Reflux & VAP

POTENTIAL MARKET SAVINGS USING LunGuard

 

$3.1b

Intensive Care Units (ICUs)

each of the companies in the chosen modalities. Medvest has a long term build strategy for each of the companies in the chosen modalities. Medvest has a long term

Intensive Care Units (ICUs)

each of the companies in the chosen modalities. Medvest has a long term build strategy for each of the companies in the 

$850m

Intensive Care Units (ICUs)

each of the companies in the chosen modalities. Medvest has a long term build strategy for each of the companies in the chosen modalities. Medvest has a long term

Intensive Care Units (ICUs)

each of the companies in the chosen modalities. Medvest has a long term build strategy for each of the companies in the 

300%

Intensive Care Units (ICUs)

each of the companies in the chosen modalities. Medvest has a long term build strategy for each of the companies in the chosen modalities. Medvest has a long term

Intensive Care Units (ICUs)

each of the companies in the chosen modalities. Medvest has a long term build strategy for each of the companies in the 

 
 

TEAM

MANAGEMENT

David Akunis (Israel)

• MP at Medvest, focus on Israel

• Previously VP & investment manager at prestigious international VC and PE firms

• Former head of the Medical and biotech equipment department at the Israeli Ministry of Export

Mario Olszakier, General Manager (Israel)

• VP Business development & marketing for Flight Medical Innovation Ltd

• Sales and marketing roles at Itamar medical Ltd.

• Key product management role at Elscint echnology

Ofer Ish Shalom, VP R&D (Israel)

• CEO of Etrog, R&D for Opto-mechanical motion & special vacuum systems

• Mechanical team lead and designer at Orbotech; built an advanced plotter for the circuit board industry

• IDF Military service-Served for 9 years at MAFAT;Administration for the development of weapons and technological infrastructure

BOARD

Barbara Faktor, Board member (Israel

• CEO of Rishonim medical center, Rishon Letzion

• Director at NIMedical

Elias Azulay, Board member (Israel)

• Managing director & General Council of Perviz Ventures

• Investor and board member of healthcare startups in Israel (Orpheus Medical,Clear-Cut Medical,Profility)

EXPERT ADVISORS

Prof. Pierre Singer, Chairman (Israel)

• Director of General Intensive care unit, Hadassah medical

Prof. Vernon van Heerden,Scientific advisor (Israel)

• Head of adult ICU,Bellinson, Israel, MD

Dr.Yaron Avitzur, Scientific advisor (Canada)

• Medical Director, Intestinal rehabilitation and transplantation, Hospital for Sick Children, Toronto

Prof. Stephen A. McClave, Scientific advisor (USA)

• Director of Clinical Nutrition at the University of Louisville School of Medicine

  • LinkedIn

Medical Investing and managing

Hospital products Home care and lifestyle health

Digital health & medtech products & services

© 2020 MEDVEST UK LLP